Results from two phase 3 trials showed that topical tapinarof, once a day, was effective and safe in patients with atopic dermatitis as young as 2 years old.
Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.
A session held at the American Academy of Dermatology Annual Meeting 2024 highlighted the ways in which atopic dermatitis can be treated and addressed in adults and older adults.
"It can be overwhelming because there are many choices but so little time," says Dr Jonathan Silverberg, of George Washington University, Washington, DC.